 Shares of Prometheus Biosciences Inc. RXDX, -4.40 soared 177.0 in premarket trading on Wednesday after the company said it will advance an experimental therapy into Phase 3 clinical trials for ulcerative colitis and Crohns disease next year. The treatment, PRA023, was both safe and efficacious in a pair of Phase 2 clinical trials for the same conditions, Prometheus said in a news release. 